Adaptive Biotechnologies (ADPT) reported its Q4 loss narrowed to $0.23 a share from the loss of $0.48 a year earlier.
Three analysts polled by FactSet expected a loss of $0.26.
Revenue in the three months ended Dec. 31 rose to $47.5 million from $45.8 million a year earlier, the company said Tuesday in a statement.
Analysts surveyed by FactSet expected $46 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.